Jakavi approved in Europe
In August 2012 Jakavi - the European name for Jakafi - was approved for use in Myelofibrosis patients throughout Europe. Jakafi was approved by the FDA in January 2012. This marks the first European Commission approved treatment for symptoms related to myelofibrosis. To read more about the approval click here.